Profile of infliximab in the treatment of pediatric Crohn’s disease

Jaroslaw Kierkus,1 Edyta Szymanska,2 Grzegorz Oracz,1 Anna Wiernicka,1 Maciej Dadalski1 1Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, 2Department of Pediatrics, Nutrition and Metabolic Disorders, The Children’s Memorial Health Institute, Warsaw, Poland Abst...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kierus J (Author), Szymanska E (Author), Oracz G (Author), Wiernicka A (Author), Dadalski M (Author)
Format:	Book
Published:	Dove Medical Press, 2015-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile
by: Luz María Medrano, et al.
Published: (2015)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn's Disease
by: Saeed Razmeh, et al.
Published: (2021)

Metastatic Crohn's disease despite infliximab therapy
by: Sara Campos, et al.
Published: (2017)

FPR1, as a Potential Biomarker of Diagnosis and Infliximab Therapy Responses for Crohn’s Disease, is Related to Disease Activity, Inflammation and Macrophage Polarization
by: Ye C, et al.
Published: (2024)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn's Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023)

Clinical utility of ustekinumab in Crohn’s disease
by: Kotze PG, et al.
Published: (2018)

Treatment of Crohn’s disease with colony-stimulating factors: An overview
by: Luisa Guidi, et al.
Published: (2008)

Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn’s Disease Patients: A Multicentre, Retrospective Study
by: Cai W, et al.
Published: (2024)

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
by: Wenhui Hu, et al.
Published: (2021)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
by: Toshihiko Kakiuchi, et al.
Published: (2021)

Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease,
by: Lucas Campos Garcia, et al.
Published: (2021)

The impact of medication belief on adherence to infliximab in patients with Crohn's disease
by: Shuyan Li, et al.
Published: (2023)

Early intestinal obstruction after infliximab therapy in Crohn's disease
by: Mitsuro Chiba, et al.
Published: (2019)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn's Disease
by: George Alex, et al.
Published: (2013)

Tracing the historical foundations of infliximab in Crohn's disease treatment: a cited reference analysis
by: Andy Wai Kan Yeung
Published: (2024)

CONTINUOUS INFLIXIMAB THERAPY FOR A 14-YEARS-OLD GIRL WITH CROHN DISEASE
by: E.N. Fedulova, et al.
Published: (2009)

CONTINUOUS INFLIXIMAB THERAPY FOR A 14-YEARS-OLD GIRL WITH CROHN DISEASE
by: E.N. Fedulova, et al.
Published: (2009)

Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection - Reply
by: M. Galeazzi
Published: (2003)

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease
by: Michał Sobjanek, et al.
Published: (2014)

Infliximab-induced intertriginous psoriasis in patient with Crohn's desease
by: Federica Mola, et al.
Published: (2011)

Burden of Crohn’s disease: economics and quality of life aspects in Italy
by: Benedini V, et al.
Published: (2012)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
by: Deepak P, et al.
Published: (2016)

A novel role of the splenic volume in Crohn's disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023)

Dietary Therapies in Pediatric Crohn's Disease
by: Izabela Kamińska, et al.
Published: (2023)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease
by: Kouzhu Zhu, et al.
Published: (2024)

An evidence-based review of natalizumab therapy in the management of Crohn’s disease
by: Raja GR Edula, et al.
Published: (2009)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease
by: Beatriz Orts, et al.
Published: (2022)

USE OF COMBINED THERAPY WITH LOCALIZED ADMINISTRATION OF INFLIXIMAB IN CHILDREN WITH CONTINUOUSLY RECURRENT PERIANAL CROHN'S DISEASE
by: O.V. Shcherbakova
Published: (2010)

USE OF COMBINED THERAPY WITH LOCALIZED ADMINISTRATION OF INFLIXIMAB IN CHILDREN WITH CONTINUOUSLY RECURRENT PERIANAL CROHN'S DISEASE
by: O.V. Shcherbakova
Published: (2010)

Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn’s Disease
by: Su T, et al.
Published: (2024)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
by: Ashley Fonseca, et al.
Published: (2021)

Clinical Features of Crohn’s Disease Stratified by Age at Diagnosis According to Montreal Classification
by: Xiang J, et al.
Published: (2023)

Identification of Targets for Subsequent Treatment of Crohn’s Disease Patients After Failure of Anti-TNF Therapy
by: Yao Y, et al.
Published: (2023)

Multiple Lesions at Different Stages of Pyoderma Gangrenosum in a Crohn’s Disease Patient
by: Zhang H, et al.
Published: (2022)

Change in the treatment strategy for pediatric Crohn's disease
by: Mi Jin Kim, et al.
Published: (2010)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN'S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients
by: Yueying Chen, et al.
Published: (2021)

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease
by: Qianqian Li, et al.
Published: (2021)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease
by: Shin Kashima, et al.
Published: (2022)

Profiling non-coding RNA levels with clinical classifiers in pediatric Crohn's disease
by: Ranjit Pelia, et al.
Published: (2021)